Carol Ann Huff
Johns Hopkins University · 210 works · 12,179 citations · h-index 49
Top works
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
- Characterization of clonogenic multiple myeloma cells
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma
- Multiple Myeloma
- Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome
- Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
- Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
- Autoproteolysis of the small subunit of calcium-dependent protease II activates and regulates protease activity.
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018
- Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- Epidemiology and Outcomes of Clostridium difficile Infections in Hematopoietic Stem Cell Transplant Recipients
- Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
- The paradox of response and survival in cancer therapeutics
- NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016
- Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide